TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9224082
Drug: Aciclovir suspension
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aciclovir suspension 15 mg/kg five times a day for seven days
Study: 26947328
Drug: Metformin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (250 mg daily)
Study: 20589368
Drug: Weekly bisphosphonates
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly bisphosphonates
Study: 20589368
Drug: Annual zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Annual zoledronic acid infusions
Study: 19430310
Drug: Torasemide (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (8 mg/d)
Study: 19430310
Drug: Azosemide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azosemide (60 mg/d)
Study: 9322191
Drug: Milk fat
Normalized name: MILK FAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fat (40 g of fat/m2 body surface area)
Study: 27693004
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (general)
Study: 10331109
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg daily) with pindolol (7.5 to 10 mg daily)
Study: 28419068
Drug: TX‐004HR 4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX‐004HR 4, 10, and 25 μg
Study: 25384338
Drug: nonhormonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nonhormonal therapy
Study: 23642343
Drug: Heparins (unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparins (unfractionated heparin, heparinoids, or low-molecular-weight heparin)
Study: 10523401
Drug: Aspirin or
Normalized name: aspirin Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin or placebo
Study: 11323369
Drug: Tramadol 1
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1 mg/kg with ondansetron 0.1 mg/kg
Study: 28785879
Drug: Doravirine 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine 1200 mg
Study: 12610241
Drug: Willingness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness to pay for depression treatment at baseline
Study: 12610241
Drug: Willingness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness to pay for depression treatment at six-month follow-up
Study: 10638900
Drug: Dextrose infusion
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose infusion (4 mg x kg(‐1) x min(‐1))
Study: 8866920
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg didanosine as a single agent
Study: 8866920
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trimethoprim + 1000 mg sulphamethoxazole
Study: 8866920
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trimethoprim + 1000 mg sulphamethoxazole + 200 mg didanosine
Study: 6504632
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin E administration (100 mg/kg/d for at least 8 weeks, first dose within 8 hours of life)
Study: 24623104
Drug: GC1113 intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC1113 intravenous 0.3-5 μg/kg
Study: 24623104
Drug: GC1113 subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC1113 subcutaneous 1-8 μg/kg
Study: 15735445
Drug: Single intrapartum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intrapartum nevirapine (NVP) dose
Study: 9660028
Drug: Control (V)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (V) - 1 U containing 10(5.4) 50% tissue culture infectious dose of vaccinia virus, administered once a week for 13 weeks and then once every 2 weeks for a total of 12 months.
Study: 25795408
Drug: Linsitinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linsitinib (150 mg oral, twice daily)
Study: 24060561
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (4 tablets of 100 mg imatinib)
Study: 24060561
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (1 tablet of 400 mg imatinib)
Study: 18986387
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m², days 1, 4, 8, and 11 for eight 3-week cycles, then days 1, 8, 15, and 22 for three 5-week cycles)
Study: 18986387
Drug: Dexamethasone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (40 mg/d, days 1-4, 9-12, and 17-20 for four 5-week cycles, then days 1-4 only for five 4-week cycles)
Study: 14668456
Drug: Four-drug regimen
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug regimen
Study: 7829945
Drug: Prednisolone tablets
Normalized name: Prednisolone Tablets
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone tablets (1 mg/kg body wt/day up to 70 mg) for six successive days, then gradually reduced over the next four days
Study: 3341273
Drug: Adriamycin (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (90 mg/m2 given over 2 days, once a month for 5 months)
Study: 17542353
Drug: Cipramil 40
Normalized name: Cipramil 40 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cipramil 40 mg
Study: 17366918
Drug: Fructose infusion
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose infusion
Study: 18591524
Drug: Vapocoolant spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapocoolant spray
Study: 28282703
Drug: Water spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water spray (placebo)
Study: 21618201
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept (125 mg SC on days 1 and 8, then weekly; plus IV loading dose ∼10 mg/kg on day 1)
Study: 21618201
Drug: Intravenous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous abatacept (∼10 mg/kg on days 1, 15, and 29, then every 4 weeks)
Study: 31039807
Drug: Intravenous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous abatacept
Study: 16961169
Drug: Gabapentin preparation
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin preparation 1 (400 mg)
Study: 16961169
Drug: Gabapentin preparation
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin preparation 2 (400 mg)
Study: 30035581
Drug: Assessment-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment-only treatment as usual (TAU)
Study: 23855131
Drug: Non-sodium restricted
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-sodium restricted diet with diuretics (sodium chloride 6500-8000 mg daily)
Study: 23855131
Drug: Sodium restricted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium restricted diet with diuretics (sodium chloride 5000 mg daily)
Study: 18563956
Drug: Intramuscular aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular aripiprazole 5 mg
Study: 18563956
Drug: Oral aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral aripiprazole 5 mg
Study: 8735776
Drug: Iron solution
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron solution with ascorbic acid added to domestic drinking water for 4 months
Study: 1750592
Drug: Midazolam 15
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 15 mg night sedation
Study: 1750592
Drug: Flunitrazepam 2
Normalized name: flunitrazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 2 mg night sedation
Study: 1750592
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam 5 mg
Study: 31135731
Drug: Tight control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight control (glucose measurements hourly and treatment for maternal glucose levels lower than 60 mg/dL or greater than 100 mg/dL)
Study: 31135731
Drug: Liberalized control
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberalized control (glucose measurements every 4 hours and treatment for maternal glucose levels lower than 60 mg/dL or greater than 120 mg/dL)
Study: 28543940
Drug: Romosozumab (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romosozumab (210 mg monthly)
Study: 23683600
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 μg daily)
Study: 22841526
Drug: 4 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL/kg of 7.2% NaCl/hydroxyethyl starch (HSH group)
Study: 10862445
Drug: Imipenem/cilastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (2 g daily)
Study: 10862445
Drug: Meropenem (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (2 g daily)
Study: 22580235
Drug: rhDNAse 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNAse 7.5 mg
Study: 17462643
Drug: T administration
Normalized name: tablet administration aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: T administration alone
Study: 10520780
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine echocardiography (LDDE)
Study: 8866632
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg PROP
Study: 8866632
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg PROP + 100 mg CAFF
Study: 8866632
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg PROP + 150 mg CAFF
Study: 1727457
Drug: Interactive videodisc
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive videodisc preparation
Study: 1727457
Drug: Noninteractive videotape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninteractive videotape preparation
Study: 6369216
Drug: BSS Plus
Normalized name: BSS Plus
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSS Plus with glucose = 400 mg/dl
Study: 6369216
Drug: BSS Plus
Normalized name: BSS Plus
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSS Plus with glucose = 100 mg/dl
Study: 9856918
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg/day
Study: 6347779
Drug: Interruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruption of continuous subcutaneous insulin infusion
Study: 22382187
Drug: Thrice-daily biphasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily biphasic human insulin (30/70, BHI)
Study: 2193979
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine (half dose)
Study: 2193979
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine (full dose)
Study: 30834817
Drug: Interactive decision
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive decision tool intervention for FTASD treatment
Study: 30834817
Drug: Text-based control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text-based control on shoulder dislocations and treatments
Study: 25833773
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplementation (20 g/d)
Study: 23890573
Drug: Triple-antiplatelet therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-antiplatelet therapy (TAT; aspirin, clopidogrel, and cilostazol)
Study: 19619377
Drug: Phone-based, nurse-led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phone-based, nurse-led educational, care coordination palliative care intervention model, provided weekly for the first month and then monthly until death, including bereavement follow-up call to the caregiver.
Study: 17502727
Drug: Antiretroviral drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral drug resistance
Study: 12202466
Drug: Risedronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (5 mg daily)
Study: 9676346
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg sustained release theophylline (Bronchoretard) administered in a fasting state
Study: 9676346
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg sustained release theophylline (Bronchoretard) administered after a standard meal
Study: 9676346
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg sustained release theophylline (Bronchoretard) administered after a high-caloric fat evening meal
Study: 8192698
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of food with theophylline
Study: 7734463
Drug: Enhanced clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced clinical services (more frequent and intensive group therapy, or adding individual treatment services)
Study: 25119509
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment with PMT
Study: 17135808
Drug: Telephonic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephonic administration of the same assessment
Study: 12923410
Drug: Hydrochlorothiazide (HCTZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ, 25-50 mg once daily)
Study: 11194516
Drug: p-HES (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-HES (1000 ml)
Study: 11194516
Drug: c-HES (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: c-HES (1000 ml)
Study: 3565455
Drug: Native intravenous
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native intravenous immunoglobulin (IVIG)
Study: 3565455
Drug: Modified intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified intravenous immunoglobulin (IVIG)
Study: 20556817
Drug: ERB-041 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERB-041 (5 mg)
Study: 20556817
Drug: ERB-041 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERB-041 (25 mg)
Study: 20556817
Drug: ERB-041 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERB-041 (75 mg)
Study: 11083963
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus nebulized salbutamol (0.2 mg/kg) and oral steroids (1 mg/kg)
Study: 8466016
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection at vastus lateralis
Study: 8466016
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection at vastus lateralis
Study: 8466016
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection at deltoid
Study: 8466016
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection at deltoid
Study: 26551446
Drug: H5N1(2) -
Normalized name: influenza, H5N1-1203
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5N1(2) - H5N1 group (2-dose priming with A/Indonesia/05/2005-H5N1-AS03B followed by booster with A/turkey/Turkey/1/2005-H5N1-AS03B)
Study: 8009573
Drug: IR propranolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR propranolol, 160 mg (Phase A)
Study: 2605788
Drug: Naloxone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (4 mg bolus and 6 mg/h)
Study: 27676631
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (up to 20 treatments within 6 months)
Study: 21350422
Drug: Neuromidin (ipidacrinum)
Normalized name: Neurokinin p
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromidin (ipidacrinum) 80 mg/day for 3 months
Study: 15623461
Drug: Combination low-fat/high-FV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination low-fat/high-FV diet
Study: 7509894
Drug: Bisoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (10 mg once daily)
Study: 10155349
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg once daily)
Study: 28829001
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 34 mg of ferrous sulfate (group A)
Study: 28829001
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of 34 mg of ferrous sulfate (group B)
Study: 21563507
Drug: Xuebijing Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing Injection
Study: 23985210
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine therapy)
Study: 12614996
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of ethyl-eicosapentaenoic acid
Study: 8409152
Drug: Intramuscular cefoperazone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular cefoperazone, 1 gm every 12 hours, for 10 days
Study: 8409152
Drug: Intramuscular ceftriaxone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ceftriaxone, 1 gm every 24 hours, for 10 days
Study: 3512778
Drug: Methylpentynol, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylpentynol, 200 mg/day
Study: 29529161
Drug: Large servings
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large servings of apple (410 g)
Study: 29529161
Drug: Large servings
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large servings of apple juice (340 mL)
Study: 12439601
Drug: 24-hour intravenous
Normalized name: 24 Hour Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour intravenous infusions of methotrexate (MTX)
Study: 30782915
Drug: STEP clinic
Normalized name: Plan B One-Step Clinic Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: STEP clinic care including self-monitoring instructions, BP monitor, sleep apnoea screening, dietary counselling, review of BP monitoring records, and medication adjustment.
Study: 29270490
Drug: QPI‐1002 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: QPI‐1002 0.5 mg/kg
Study: 29270490
Drug: QPI‐1002 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: QPI‐1002 1.5 mg/kg
Study: 21402549
Drug: rAd5 HIV-1
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAd5 HIV-1 gag vaccine
Study: 17916806
Drug: salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol/fluticasone propionate 50/500 microg twice daily
Study: 12616578
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) with nonexposure-based treatment
Study: 12616578
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) with both exposure and nonexposure-based treatments
Study: 11127455
Drug: Transvaginal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transvaginal progesterone gel (90 mg on alternate days) with estradiol (1 mg/day for three weeks then 2 mg/day for one week)
Study: 8262689
Drug: Morphine, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine, 0.2 mg/kg-1
Study: 12122623
Drug: NaCl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl (2 ml of 0.9% NaCl applied eight times daily)
Study: 8831437
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with nortriptyline
Study: 26988845
Drug: L-based supplement
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-based supplement
Study: 21459588
Drug: Boron neutron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron neutron capture therapy (BNCT)
Study: 17485918
Drug: Radioiodine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine treatment (3.3-5.6 GBq)
Study: 15205198
Drug: Paclitaxel-Carboplatin (CRP-PCT)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paclitaxel-Carboplatin (CRP-PCT) - CRP 6 AUC and PCT 175 mg/m² every 3 weeks for six cycles
Study: 15205198
Drug: Paclitaxel-Vinorelbine (VRL-PCT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel-Vinorelbine (VRL-PCT) - VRL 25 mg/m² and PCT 135 mg/m² every 2 weeks for nine cycles
Study: 7986470
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion with 3% saline infusion (0.1 mL/kg/min)
Study: 7986470
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (2 ng/kg/min) alone
Study: 2645421
Drug: Enoxacin 400
Normalized name: enoxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin 400 mg orally every 12 hours for 14 days
Study: 2645421
Drug: Trimethoprim 160
Normalized name: trimethoprim 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 160 mg plus Sulfamethoxazole 800 mg
Study: 31992372
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (20 g/d)
Study: 24469530
Drug: Residual insomnia
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual insomnia symptoms after treatment
Study: 9440372
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g fat meal
Study: 9440372
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g fat meal
Study: 9440372
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g fat meal